Company Focus
AbbVie
Latest AbbVie News
Pharmaceutical
The US medicines regulator has approved Linzess (linaclotide) capsules for children aged seven years and older with irritable bowel syndrome with constipation. The move marks the first authorized treatment for pediatric patients with the condition. 6 November 2025
Related News
Insights
Company Spotlight
A biopharma company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology.
Latest News & Features of interest to AbbVie
Biotechnology
The US Food and Drug Administration (FDA) has approved Johnson & Johnson’s Darzalex Faspro (daratumumab and hyaluronidase-fihj) as a single agent treatment for adult patients with high-risk smoldering multiple myeloma (HR-SMM). 7 November 2025
Biotechnology
Danish biotech Genmab reported a 25% rise in its total revenue to $1.02 billion during the third quarter of 2025, ahead of analysts’ expectations for $966 million. 7 November 2025
Pharmaceutical
Healthcare giant Johnson & Johnson has announced that the US Food and Drug Administration (FDA) has approved Caplyta (lumateperone) as an adjunctive therapy with antidepressants for the treatment of major depressive disorder (MDD) in adults. 7 November 2025
Pharmaceutical
The global endometrial cancer market is on course for steady expansion, projected to reach nearly $39 billion by 2030. Growth is being fueled by rising incidence rates linked to aging populations, obesity, and metabolic conditions, alongside expanding use of targeted and immuno-oncology therapies in key regions, particularly the USA. 7 November 2025
Pharmaceutical
Belgian biopharma company UCB has announced a leadership reshuffle, effective January 1, 2026, as part of a plan to reinforce cross-functional collaboration and sustain growth. 7 November 2025
Pharmaceutical
Anglo-Swedish pharma major AstraZeneca closed Thursday’s trading 3% higher, as investors digested its third quarter financial results. 6 November 2025
Pharmaceutical
The Russian government has approved the allocation of 140 billion roubles ($1.72 billion) annually for the treatment of cancer patients for years to come. 6 November 2025
Pharmaceutical
Arena BioWorks, a privately funded biomedical research institute that aimed to overhaul the traditional drug discovery model, has closed its doors less than two years after its $500 million launch. The decision follows what its founding investor group called “dramatic changes” in biotech market conditions, with no clear recovery in sight. 6 November 2025
Pharmaceutical
Australian biotech PolyActiva and USA-based RareSight have formed a strategic collaboration to create first-in-class treatments for inherited retinal diseases in children. The research will apply PolyActiva’s proprietary Prezia sustained-release platform to generate new pro-drugs that can be delivered directly to the retina. 6 November 2025
Pharmaceutical
The US medicines regulator has approved Linzess (linaclotide) capsules for children aged seven years and older with irritable bowel syndrome with constipation. The move marks the first authorized treatment for pediatric patients with the condition. 6 November 2025
Latest In Brief for AbbVie
Pharmaceutical
US biopharma Soligenix has priced a $7.5 million public offering. Proceeds will fund research, commercialization, and corporate purposes, with A.G.P./Alliance Global Partners acting as sole placement agent. 26 September 2025
Latest Related Ones To Watch News
Arena BioWorks, a privately funded biomedical research institute that aimed to overhaul the traditional drug discovery model, has closed its doors less than two years after its $500 million launch. The decision follows what its founding investor group called “dramatic changes” in biotech market conditions, with no clear recovery in sight. 6 November 2025
25 October 2025
23 October 2025
22 October 2025
17 October 2025
Related Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze